TELA Bio, Inc. provided earnings guidance for the three months ended March 31, 2023. For the period, the company estimated revenue to be $11.9 million, compared to $8.2 million over the corresponding period of 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.485 USD | -0.81% | -5.05% | -17.67% |
20/05 | TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer | CI |
10/05 | Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.67% | 136M | |
-6.34% | 178B | |
-0.04% | 107B | |
-1.22% | 67.04B | |
-6.54% | 47.23B | |
+11.49% | 44.62B | |
+9.25% | 42.5B | |
+15.45% | 29.99B | |
+15.97% | 25.22B | |
-5.71% | 24.14B |
- Stock Market
- Equities
- TELA Stock
- News TELA Bio, Inc.
- TELA Bio, Inc Provides Earnings Guidance for the Three Months Ended March 31, 2023